While a number of research institutes are racing to come up with a potential vaccine for the novel virus, the U.S news portals dropped news which came good news for the citizens under panic. According to the reports, the National Institute of Allergy and Infectious Diseases (NIAID) tested their dose of experimental vaccine on the first human on Tuesday. While making a jump from the animal models to the humans, the research institute claimed that it came a step closer in bringing the vaccine to market.
The team of researchers from Seattle, Washington in the United States has given the first clinical trials of a vaccine on Jennifer Haller, a techie who volunteered who said that she feels lucky to be in a position to contribute to containing the outbreak. The 43-year-old mother will be taken into observation for the next 18 months to track the developments.
This has welcomed equal amount of criticism as the federal regulators allowed NIH and Moderna(biotechnology company which has developed the vaccine) to go straight from the lab to human clinical trials, without waiting for experiments with lab animals to run their course.
NIAID issued an official statement over the same stating that it is phase-1 of the clinical trials which mainly concentrates to provide information about how the vaccine interacts with a healthy human body. In addition to monitoring for side effects, the researchers will test whether the vaccine triggers an immune response by analyzing the volunteers’ blood for antibodies.